Muhammad Musa Khan | Drug Safety and Risk Management | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Muhammad Musa Khan | Drug Safety and Risk Management | Best Researcher Award

Associate Researcher at Hainan Institute of Zhejiang University | China

Dr. Muhammad Musa Khan is a Pakistani entomologist and research scientist with an extensive background in agricultural entomology, insect toxicology, and pest management. Currently serving as an Associate Researcher at the Hainan Institute of Zhejiang University, China, he focuses on pesticide toxicity, ecological risk assessment, and resistance management in agroecosystems. His research spans ecological, molecular, and toxicological approaches to pest control. Dr. Khan has published prolifically in high-impact journals and is recognized for advancing sustainable pest management strategies. His collaborative, multidisciplinary work integrates field ecology with molecular diagnostics, benefiting both science and agriculture on a global scale.

Publication Profile 

Google Scholar

Education 

Dr. Khan earned his Ph.D. in Agricultural Entomology and Pest Control from Huazhong Agricultural University, China, where he worked on predator safety in rice ecosystems. He completed his M.Sc. (Hons) in Entomology from the University of Agriculture Faisalabad, Pakistan, researching resistance mechanisms in cotton against sap-sucking pests. His undergraduate degree (B.Sc. Hons) in Agriculture with a specialization in Entomology was obtained from PMAS Arid Agriculture University, Rawalpindi. Additionally, he interned at the Nuclear Institute for Agriculture and Biology, gaining hands-on expertise in biological control agent rearing and field application methods.

Experience 

Dr. Khan currently serves as Associate Researcher at the Hainan Institute of Zhejiang University, China, investigating pesticide toxicity and resistance in brown planthopper and rice ecosystems. His previous role as a Postdoctoral Researcher at South China Agricultural University involved studying the effects of UV light on whiteflies and moths. During his Ph.D., he explored ecotoxicological risks of insecticides on beneficial insects and tested essential oil-based pest repellent strategies. His scientific skillset encompasses molecular biology techniques, gene expression analysis, bioinformatics, and biostatistics. His interdisciplinary approach allows integration of molecular diagnostics with field-level pest management.

Awards and Honors 

Dr. Khan has received significant recognition for his impactful research, including editorial contributions to international journals such as Frontiers in Plant Science. His publications have consistently appeared in top-tier Q1 journals like Journal of Hazardous Materials and Chemosphere. As a corresponding author and equal first author, his contributions are well-acknowledged in international collaborations. His work has received citations and global visibility for its originality in ecological toxicology and entomological innovation. Moreover, his involvement in multiple Chinese institutions and his role in international research networks reflect his growing influence and leadership in the agricultural research community.

Research Focus 

Dr. Khan’s research bridges entomology, toxicology, and molecular biology with a primary focus on insecticide resistance, non-target toxicity, and ecological safety in agroecosystems. He specializes in assessing chemical and environmental stressors on pests and their natural enemies, especially in rice and vegetable production systems. His studies utilize DNA/RNA techniques, gene expression profiling, and biochemical assays to decipher the molecular impact of pesticides and ultraviolet exposure on pest physiology and behavior. He is particularly interested in predator-prey dynamics, pollinator safety, integrated pest management, and sustainable solutions to enhance agricultural productivity while minimizing ecological harm.

Publication Top Notes

Role of insect gut microbiota in pesticide degradation: a review

Metabolic-based insecticide resistance mechanism and ecofriendly approaches for controlling of beet armyworm Spodoptera exigua: a review

Impact of invasive ant species on native fauna across similar habitats under global environmental changes

Lethal and sublethal effects of emamectin benzoate on the rove beetle, Paederus fuscipes, a non-target predator of rice brown planthopper, Nilaparvata lugens

Identification of attractants from plant essential oils for Cyrtorhinus lividipennis, an important predator of rice planthoppers

Role of digestive protease enzymes and related genes in host plant adaptation of a polyphagous pest, Spodoptera frugiperda

Temperature-Dependent Functional Response of Harmonia axyridis (Coleoptera: Coccinellidae) on the Eggs of Spodoptera litura (Lepidoptera: Noctuidae) in …

Lethal and Sublethal Effects of Chlorpyrifos on Biological Traits and Feeding of the Aphidophagous Predator Harmonia axyridis

Sublethal effects of chlorantraniliprole on Paederus fuscipes (Staphylinidae: Coleoptera), a general predator in paddle field

Using a Two-Sex Life Table Tool to Calculate the Fitness of Orius strigicollis as a Predator of Pectinophora gossypiella

Insecticide resistance and detoxification enzymes activity in Nilaparvata lugens Stål against neonicotinoids

Emamectin benzoate induced enzymatic and transcriptional alternation in detoxification mechanism of predatory beetle Paederus fuscipes (Coleoptera: Staphylinidae) at the …

Bright E IGERE | Antibiotic Resistance | Best Researcher Award

Published on by Top Pharmaceutical

Assist. Prof. Dr. Bright E IGERE | Antibiotic Resistance | Best Researcher Award

Senior Lecturer at Delta State University | Nigeria

Assist. Prof. Dr. Bright E. Igere is a distinguished microbiologist and academic with a strong background in microbial genetics, molecular epidemiology, and biotechnology. He currently serves in a pivotal role within his university’s Research and Publication Board and Result Quality Assurance Committee. A dedicated scholar, Dr. Igere has contributed extensively to the scientific community through his multidisciplinary research and peer-reviewed publications. His work spans national and international journals, focusing on antimicrobial resistance, public health, and environmental microbiology. A recipient of several prestigious awards and fellowships, he is committed to advancing scientific knowledge and mentoring the next generation of microbiologists.

Publication Profile 

Google Scholar

Education 

Dr. Bright E. Igere earned his Ph.D. in Microbiology from the University of Fort Hare, South Africa, specializing in microbial genetics and molecular epidemiology. He completed his M.Sc. in Microbiology at Delta State University Abraka, Nigeria, where his research centered on microbial genetics. he obtained a B.Tech. in Biotechnology from Nnamdi Azikiwe University, Awka, a CGPA. He completed his secondary education at Edjeba Secondary School and primary education at Oharisi Modern Primary School, earning his First School Leaving Certificate.

Experience 

Dr. Igere has held multiple academic and administrative roles, currently serving as Secretary of the Research/Publication Board and as a member of the Result Quality Assurance Committee. With extensive experience in microbial research and diagnostics, he has supervised postgraduate theses and mentored young scientists. His work extends beyond teaching into collaborative research, editorial reviews, and institutional governance. Dr. Igere has contributed significantly to microbiological research involving both clinical and environmental isolates, and his collaborations span local and international institutions. His experience in academia is enriched by policy development, grant acquisition, and community health-related research in microbiology and public health.

Awards and Honors 

Dr. Bright E. Igere has received numerous awards and fellowships in recognition of his scientific contributions. He received the AGNES Grant by the African-German Network of Excellence in Science and the Elsevier Reviewers Award. he was honored with a Supervisor-Linked Bursary from the South African Medical Research Council. That same year, he was named Best Emerging Young Researcher in Biological Sciences. He was also awarded an inter-cadre transfer by the Natural Science board and received funding and recognition from Western Delta University for outstanding contributions to molecular training and scientific growth.

Research Focus 

Dr. Igere’s research revolves around microbial genetics, molecular epidemiology, antimicrobial resistance, and biofilm-associated infections. He explores public and environmental health microbiology, focusing on emerging pathogens, toxin-producing strains, and multidrug-resistant organisms in clinical and aquatic ecosystems. His work emphasizes molecular characterization, virulence dynamics, and pathogen surveillance. He has conducted studies on Vibrio cholerae, Bacillus cereus, Klebsiella, and MRSA strains, advancing biofilm therapeutics and eco-health implications. His interdisciplinary research integrates genomics, environmental microbiology, and biotechnology to develop novel therapeutic strategies and inform disease control frameworks. Dr. Igere’s work contributes significantly to global health, food safety, and environmental monitoring.

Publication Top Notes

Prevalence of Multiple Antibiotics Resistant (MAR) Pseudomonas Species in the Final Effluents of Three Municipal Wastewater Treatment Facilities in South Africa

Virulence and Antibiotic Resistance Characteristics of Vibrio Isolates From Rustic Environmental Freshwaters

Antimicrobial and phytochemical evaluation of the leaf, stem bark and root extracts of Cyathula prostrata (L) Blume against some human pathogens

Antibiotic Susceptibility Testing (AST) Reports: A Basis for Environmental/Epidemiological Surveillance and Infection Control Amongst Environmental Vibrio cholerae

Human norovirus contamination in wate8r sources: A systematic review and meta-analysis

Wastewater treatment plants and release: The vase of Odin for emerging bacterial contaminants, resistance and determinant of environmental wellness

Non-serogroup O1/O139 agglutinable Vibrio cholerae: a phylogenetically and genealogically neglected yet emerging potential pathogen of clinical relevance

Meta-synthesis and science mapping analysis of HIV/HPV co-infection: a global perspective with emphasis on Africa

Occurrence, Antibiotic Susceptibility and Genes Encoding Antibacterial Resistance of Salmonella spp. and Escherichia coli From Milk and Meat Sold in Markets of …

Global mapping of cholera vibrio and outbreaks in the pre-millennium development goals (MDG)/sustainable development goals (SDG) and MDGs/SDGs era of 1990–2019

Subrata Kar | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Subrata Kar | Clinical Trials | Best Researcher Award

Subrata Kar at Virginia Commonwealth University | United States

Dr. Subrata Kar is a distinguished interventional cardiologist and academic leader currently serving as Associate Professor of Medicine at Virginia Commonwealth University and Interventional Cardiologist at the Veterans Affairs Medical Center in Richmond, Virginia. With specialization in structural heart disease, peripheral vascular intervention, and advanced heart failure and transplant cardiology, Dr. Kar has held leadership roles at multiple prestigious institutions including UCLA, Texas Tech University, and NYC Health + Hospitals. He has been instrumental in launching advanced cardiology programs, mentoring trainees, and leading clinical and academic departments. His work reflects a deep commitment to patient care, education, and cardiovascular innovation.

Publication Profile 

Orcid

Education 

Dr. Kar earned his Doctor of Osteopathic Medicine from the New York College of Osteopathic Medicine, where he also completed a Neuroanatomy Fellowship. He holds dual bachelor’s degrees in Bio-Mathematics and Biology from Rutgers University. His post-graduate training includes an internal medicine residency at the Cleveland Clinic, followed by a cardiovascular medicine fellowship at the University of Missouri-Columbia. He further specialized with interventional cardiology fellowships at Stony Brook University and UCLA, where he also trained in structural and congenital heart disease. Additionally, he completed an advanced heart failure and transplant cardiology fellowship at NYU Langone Medical Center.

Experience 

Dr. Kar has served in diverse clinical, academic, and leadership roles across major medical institutions in the U.S. Currently an Interventional Cardiologist and Advanced Heart Failure specialist at VCU/VA Medical Center, he previously held senior positions at Middletown Medical, NYC Health + Hospitals, Texas Tech University, and UCLA. His roles have included Division Chief, Director of Interventional Cardiology, and Chair of Fellowship Selection Committees. He has also worked as a hospitalist at the Cleveland Clinic and a clinical instructor at UCLA. His experience reflects comprehensive expertise in interventional cardiology, structural heart interventions, and academic program development.

Awards and Honors 

Dr. Kar has received recognition for both clinical excellence and academic leadership. At UCLA and Texas Tech, he was instrumental in program development and fellowship training, earning him leadership roles such as Chair of the Academic Cardiology Section of the American College of Cardiology (Texas Chapter). He has been invited to present at national cardiology conferences and served on key committees evaluating trainee competency. His pioneering clinical program launches, particularly in interventional cardiology at Coney Island Hospital, highlight his innovation and impact. His mentorship and contributions to cardiology education have also been widely commended by academic and hospital leadership.

Research Focus 

Dr. Kar’s research centers on structural heart disease, adult congenital heart defects, interventional cardiology techniques, and advanced heart failure therapies. He has explored minimally invasive cardiovascular interventions, radiation reduction in catheterization procedures (KAR RAD study), and cardiac CT applications. He has presented nationally on outcomes in percutaneous valve procedures and congenital heart disease management. His work also includes developing safety protocols and training programs in cardiac catheterization labs. Through his research, he integrates clinical innovation with academic insight, advancing cardiovascular treatment and education, especially in underserved populations. His mentoring of trainees in research further amplifies his academic reach.

Publication Top Notes

Application and Outcomes of Minimal-Dose Versus Standard-Dose Radiation in Peripheral Endovascular Intervention (KAR Endovascular Study)

Kelly Yoo | Precision Medicine | Best Scholar Award

Published on by Top Pharmaceutical

Dr. Kelly Yoo | Precision Medicine | Best Scholar Award

Kelly Yoo at Stanford University | United States

Dr. Kelly H. Yoo is a physician-scientist specializing in neurosurgery and neuro-oncology, currently conducting postdoctoral research at Stanford University. Her work bridges translational neuroscience, radiosurgery, and artificial intelligence in clinical applications. She has authored numerous peer-reviewed articles and case studies on stereotactic radiosurgery, spinal disorders, and brain metastases. Dr. Yoo has received multiple international awards and fellowships for her academic excellence and research leadership. As a committed member of professional organizations and advisory boards, she contributes to global health, clinical innovation, and medical education. Her research efforts aim to improve patient outcomes through technology-enhanced, precision-targeted therapies.

Publication Profile 

Scopus

Education 

Dr. Kelly Yoo earned her International Baccalaureate Diploma and graduated. She later obtained her MD with top distinction and completed her Doctorate (Dr. med., magna cum laude) from Heidelberg University School of Medicine. Her academic path included rigorous clinical, research, and methodological training. She completed multiple advanced certifications, including GCP, IRB, and Clinical Trial Investigator courses. She studied Fundamental Neuroscience for Neuroimaging at Johns Hopkins University and holds licenses and fellowships from institutions in Germany and the U.S., further enhancing her global medical and scientific competency.

Experience 

Dr. Yoo currently serves as a postdoctoral fellow at Stanford University, focusing on clinical and translational research in neurosurgery. She completed a clinician-scientist residency track in Baden-Württemberg and has worked across Europe and North America in academic medical centers. She is active in multiple professional societies, including AANS, CNS, and EANO. Dr. Yoo has held leadership roles in Stanford’s postdoc community and initiated several mentorship and international programs. Her academic career includes significant contributions to radiosurgical research and spinal navigation, leveraging both clinical experience and data-driven methodologies to explore innovative therapeutic solutions.

Awards and Honors 

Dr. Kelly Yoo has received numerous prestigious accolades, including the SPARK at Stanford Grant Award, Wu Tsai Neurosciences Interdisciplinary Fellowship, and multiple scholarships from the German Academic International Network (GAIN). She was also awarded the E-Fellows Gifted Education Scholarship and earned top academic distinctions from Heidelberg University and the International Baccalaureate program. She has consistently ranked in the top percentile across educational stages and received first-place honors in international mathematics competitions. Her recognitions reflect a long-standing commitment to academic excellence, scientific innovation, and leadership in neuroscience, medicine, and global health initiatives.

Research Focus 

Dr. Yoo’s research primarily centers on stereotactic radiosurgery, neuro-oncology, spinal disorders, and the integration of AI and neuroimaging into surgical planning and treatment. She investigates the clinical applications of advanced radiological techniques in treating recurrent and metastatic brain and spinal tumors. Her recent work explores synergistic effects between radiosurgery and immunotherapy and the cost-effectiveness of neurosurgical interventions. She also contributes to studies on spinal navigation, robotic-assisted surgery, and PET/MRI-guided interventions. Her interdisciplinary focus aims to enhance precision medicine and outcome prediction models in neurosurgery by blending clinical insight with computational innovation.

Publication Top Notes

Suspected and surgically managed cauda equina syndrome nationwide: epidemiological trends and socioeconomic factors influencing access to care

Trends in Sacroiliac Joint Fusion Costs and Utilization in the Privately Insured Population

Song Guo Zheng | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Song Guo Zheng | Drug Discovery and Development | Best Researcher Award

Chair Professor at Shanghai Jiao Tong University School of Medicine | China

Prof. Song Guo Zheng, M.D., Ph.D., is an internationally renowned immunologist and clinician-scientist specializing in rheumatology, molecular immunology, and translational medicine. He currently serves as Chair Professor and Dean of the School of Cell and Gene Therapy at Shanghai Jiao Tong University. With academic leadership roles across prestigious institutions in the U.S. and China, his pioneering work spans autoimmunity, cell therapy, and immunoregulation. A prolific author with over 110 peer-reviewed publications in top-tier journals, Prof. Zheng is also a highly decorated researcher and active leader in global immunology societies. His contributions continue to shape modern immunotherapy and precision medicine.

Publication Profile 

Google Scholar

Orcid

Education 

Prof. Zheng earned his Ph.D. in Molecular Immunology from the University of Orleans, France (2011), and a Master’s in Pathology and Immunology from Shanghai Medical University (1992). He completed his M.D. at Anhui Medical University (1984). His clinical training included a residency in surgery at Chizhou City Hospital (1984–1989) and an internship at Shanghai Zhabei Hospital (1983–1984). He further pursued a pathology fellowship at Shanghai Medical University Cancer Hospital (1989–1993). These academic and clinical foundations laid the groundwork for a distinguished career in immunology, clinical research, and translational medicine across both China and the United States.

Experience 

Prof. Zheng currently serves as Chair Professor at Shanghai Jiao Tong University and Dean of the School of Cell and Gene Therapy (2023–Present). He previously held senior positions including the Ronald L. Whisler Chair in Rheumatology and Immunology at Ohio State University (2018–2022) and Director at Penn State University’s College of Medicine (2013–2018). His U.S. academic journey began at the University of Southern California as an assistant and associate professor (2004–2013), after postdoctoral work at USC and UCLA. With leadership in research, teaching, and clinical science, he has become a global authority in immunological therapeutics and rheumatology.

Awards

Prof. Zheng has received numerous prestigious honors, including the Outstanding Scientist Award (2023, USA) and the Distinguished Clinical Immunologist Award (2019, China). He was awarded the Edmund L. Dubois Award (2019), NIH STAR Award (2016–2021), and was Chair of NIH MOSS Study Section (2016). Notably, he earned the James R. Klinenberg Award for best immunologist in Southern California (2007) and the Freda Newton Memorial Scholar Award (2006). He is an elected member of The Henry Kunkel Society (2012) and a recipient of the ACR Investigator Award (2008–2010), reflecting his impactful and sustained contributions to clinical immunology.

Research Focus 

Prof. Zheng’s research centers on molecular immunology, particularly in autoimmune diseases, Treg/Th17 cell modulation, and immune tolerance mechanisms. He investigates immunometabolism, gene and cell therapy, and inflammatory signaling pathways with an emphasis on clinical translation. His studies on cytokines, nanomedicine, and immune checkpoint regulation aim to advance precision therapeutics for rheumatic and inflammatory diseases. He integrates cutting-edge techniques including single-cell sequencing, CRISPR-based modulation, and nano-drug delivery systems. His innovative research is highly cited and supports next-generation treatments for autoimmunity, cancer immunotherapy, and organ-specific inflammation, shaping global trends in immune-based medical interventions.

Publication Top Notes

Natural and induced CD4+ CD25+ cells educate CD4+ CD25− cells to develop suppressive activity: the role of IL-2, TGF-β, and IL-10

IL-2 is essential for TGF-β to convert naive CD4+ CD25− cells to CD25+ Foxp3+ regulatory T cells and for expansion of these cells

Role of vitamin A in the immune system

Generation ex vivo of TGF-β-producing regulatory T cells from CD4+ CD25− precursors

Vitamin D and chronic diseases

TGF-β requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+ CD25+ regulatory cells

Natural and TGF-β–induced Foxp3+ CD4+ CD25+ regulatory T cells are not mirror images of each other

Role of TNF–TNF receptor 2 signal in regulatory T cells and its therapeutic implications

Cutting edge: Foxp3+ CD4+ CD25+ regulatory T cells induced by IL-2 and TGF-β are resistant to Th17 conversion by IL-6

Hall of fame among pro-inflammatory cytokines: interleukin-6 gene and its transcriptional regulation mechanisms

The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3

The role of the combination of IL-2 and TGF-β or IL-10 in the generation and function of CD4+ CD25+ and CD8+regulatory T cell subsets

Conclusion

Given his outstanding scientific productivity, leadership in global immunology communities, and groundbreaking research on immune regulation, Prof. Song Guo Zheng is highly suitable for the Best Researcher Award. His body of work demonstrates not only scientific depth and innovation but also sustained impact on the field of immunology and clinical medicine. With ongoing contributions and strategic improvements, he remains a central figure in advancing immune-based therapies and education worldwide.